

Highlights of This Issue 531

REVIEW

- 533** Genomically Driven Tumors and Actionability across Histologies: *BRAF*-Mutant Cancers as a Paradigm
Michelle L. Turski, Smruti J. Vidwans, Filip Janku, Ignacio Garrido-Laguna, Javier Munoz, Richard Schwab, Vivek Subbiah, Jordi Rodon, and Razelle Kurzrock

SMALL MOLECULE THERAPEUTICS

- 548** Dissecting Therapeutic Resistance to ERK Inhibition
Sharda Jha, Erick J. Morris, Alan Hruza, My Sam Mansueto, Gottfried K. Schroeder, Jaren Arbanas, Daniel McMasters, Clifford R. Restaino, Priya Dayananth, Stuart Black, Nathaniel L. Elsen, Anthony Mannarino, Alan Cooper, Stephen Fawell, Leigh Zawel, Lata Jayaraman, and Ahmed A. Samatar
- 560** Targeting the Nuclear Import Receptor Kpn β 1 as an Anticancer Therapeutic
Pauline J. van der Watt, Alicia Chi, Tamara Stelma, Catherine Stowell, Erin Strydom, Sarah Carden, Liselotte Angus, Kate Hadley, Dirk Lang, Wei Wei, Michael J. Birrer, John O. Trent, and Virna D. Leaner
- 574** Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53
Goutam Karan, Huaiyu Wang, Amit Chakrabarti, Sukanya Karan, Zhigang Liu, Zhiqiang Xia, Mahesh Gundluru, Stephen Moreton, Yogen Sauntharajah, Mark W. Jackson, Mukesh K. Agarwal, and David N. Wald
- 583** Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Antje M. Wengner, Gerhard Siemeister, Marcus Koppitz, Volker Schulze, Dirk Kosemund, Ulrich Klar, Detlef Stoeckigt, Roland Neuhaus, Philip Lienau, Benjamin Bader, Stefan Pechtl, Marian Raschke, Anna-Lena Frisk, Oliver von Ahsen, Martin Michels, Bertolt Kreft, Franz von Nussbaum, Michael Brands, Dominik Mumberg, and Karl Ziegelbauer
- 593** Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
Natalie A. Jabbour-Leung, Xian Chen, Tuyen Bui, Yufeng Jiang, Dong Yang, Smruthi Vijayaraghavan, Mark J. McArthur, Kelly K. Hunt, and Khandan Keyomarsi

- 608** An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors
Jerzy O. Szablowski, Jevgenij A. Raskatov, and Peter B. Dervan
- 618** Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma
Hee Dong Han, Young-Jae Cho, Sung Keun Cho, Yeongseon Byeon, Hat Nim Jeon, Hye-Sun Kim, Byoung-Gie Kim, Duk-Soo Bae, Gabriel Lopez-Berestein, Anil K. Sood, Byung Cheol Shin, Yeong-Min Park, and Jeong-Won Lee
- 628** Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi, Nilla Avanzi, Nadia Amboldi, Maria Beatrice Saccardo, Daniele Casero, Paolo Orsini, Tiziano Bandiera, Luca Mologni, David Anderson, Ge Wei, Jason Harris, Jean-Michel Vernier, Gang Li, Eduard Felder, Daniele Donati, Antonella Isacchi, Enrico Pesenti, Paola Magnaghi, and Arturo Galvani
- 640** *In Vitro* and *In Vivo* Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer
Chun-Rong Wang, Javed Mahmood, Qin-Rong Zhang, Ali Vedadi, Jenny Warrington, Ning Ou, Robert G. Bristow, David A. Jaffray, and Qing-Bin Lu
- 651** Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity
Mariangela Garofalo, Barbara Iovine, Lukasz Kuryk, Cristian Capasso, Mari Hirvonen, Andrea Vitale, Marjo Yliperttula, Maria Assunta Bevilacqua, and Vincenzo Cerullo

LARGE MOLECULE THERAPEUTICS

- 661** ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya, Michael J. Mitten, Suzanne Norvell, Hugh D. Falls, Peter J. DeVries, Dong Cheng, Jonathan A. Meulbroek, Fritz G. Buchanan, Laura M. McKay, Neal C. Goodwin, and Edward B. Reilly

Table of Contents

670 Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy

Lorena Simón-Gracia, Hedi Hunt, Pablo D. Scodeller, Jens Gaitzsch, Gary B. Braun, Anne-Mari A. Willmore, Erkki Ruoslahti, Giuseppe Battaglia, and Tambat Teesalu

680 SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts

Harrison Kim, Sharon Samuel, Pedro Lopez-Casas, William Grizzle, Manuel Hidalgo, Joy Kovar, Denise Oelschlager, Kurt Zinn, Jason Warram, and Donald Buchsbaum

689 A Potent HER3 Monoclonal Antibody That Blocks both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

Zhan Xiao, Rosa A. Carrasco, Kevin Schifferli, Krista Kinner, Ravinder Tammali, Hong Chen, Ray Rothstein, Leslie Wetzel, Chunying Yang, Partha Chowdhury, Ping Tsui, Philipp Steiner, Bahija Jallal, Ronald Herbst, Robert E. Hollingsworth, and David A. Tice

702 Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

Aysegül İlhan-Mutlu, Matthias Osswald, Yunxiang Liao, Miriam Gömmel, Martin Reck, David Miles, Paola Mariani, Luca Gianni, Beatrix Lutiger, Viktor Nendel, Stefanie Srock, Pablo Perez-Moreno, Frits Thorsen, Louisa von Baumgarten, Matthias Preusser, Wolfgang Wick, and Frank Winkler

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

711 Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma

Shirong Li, Jing Fu, Caisheng Lu, Markus Y. Mapara, Shahzad Raza, Ulrich Hengst, and Suzanne Lentzsch

720 Targeting Interleukin-11 Receptor- α Impairs Human Endometrial Cancer Cell Proliferation and Invasion *In Vitro* and Reduces Tumor Growth and Metastasis *In Vivo*

Amy L. Winship, Michelle Van Sinderen, Jacqueline Donoghue, Kate Rainczuk, and Evdokia Dimitriadis

731 Targeting Androgen Receptor (AR) \rightarrow IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression

Liang Shi, Hui Lin, Gonghui Li, Ren-An Jin, Junjie Xu, Yin Sun, Wen-Lung Ma, Shuyuan Yeh, Xiujun Cai, and Chawnschang Chang

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

743 Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience



Maria Schwaederle, Barbara A. Parker, Richard B. Schwab, Gregory A. Daniels, David E. Piccioni, Santosh Kesari, Teresa L. Helsten, Lyudmila A. Bazhenova, Julio Romero, Paul T. Fanta, Scott M. Lippman, and Razelle Kurzrock

MODELS AND TECHNOLOGIES

753 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors



David Onion, Richard H. Argent, Alexander M. Reece-Smith, Madeleine L. Craze, Robert G. Pineda, Philip A. Clarke, Hari L. Ratan, Simon L. Parsons, Dileep N. Lobo, John P. Duffy, John C. Atherton, Andrew J. McKenzie, Rajendra Kumari, Peter King, Brett M. Hall, and Anna M. Grabowska


 AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

Overlay of the structures of SCH772984 (orange) and VIX-11e (green) revealed that upon binding of SCH772984 to ERK2, Tyr34 undergoes a rotation in the poly-Gly-rich loop creating a new binding pocket for SCH772984. This unique binding mode by SCH772984 is not observed when VIX-11e binds to ERK2. For details, see the article by Jha, Morris, and colleagues beginning on page 548.



Molecular Cancer Therapeutics

15 (4)

Mol Cancer Ther 2016;15:531-763.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/15/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/15/4>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.